A new study published in Science Advances has investigated one of the still poorly understood aspects of cancer, therapy-induced senescence in tumor cells. The study, the result of collaboration between researchers from Politecnico ...
Sep 14, 2023
0
28
When Michel Sadelain began his decades-long quest to genetically modify immune cells to fight cancer, his peers dismissed his ideas as absurd and even his mother grew concerned for his career.
Sep 14, 2023
0
24
An international team of researchers has demonstrated that a combination of inhibitors may suppress tumor growth and prevent relapse in patients with certain cancers, including head and neck squamous cell carcinoma and lung ...
Sep 12, 2023
0
0
Since its discovery in 1910, sickle cell disease has been considered a death sentence for those that inherited it. But over the years, dedicated pediatric programs and research initiatives have greatly improved patient care ...
Sep 11, 2023
0
1
A new editorial paper titled "Latest updates on MET targeted therapy for EXON 14 mutations in lung cancer" has been published in Oncotarget.
Sep 11, 2023
0
13
A small number of HIV-infected cells remain in the tissues of people living with the virus and who are undergoing antiretroviral therapy. These viral reservoirs, real obstacles to the cure of HIV, have long been known to ...
Sep 11, 2023
0
46
In a randomized trial, published in The Lancet Oncology, Mayo Clinic Comprehensive Cancer Center researchers uncover evidence supporting a shorter treatment time for breast cancer patients.
Sep 8, 2023
0
63
"I did this research by chance. I was enrolled at the Koch Institute for Integrative Cancer Research at MIT for my postdoctoral work to develop electrical devices with biotechnology. The institute is focused on cancer research ...
Sep 8, 2023
0
3
To live with type 1 diabetes is to be ruled by relentless routine. Food must be carefully monitored, and the only treatment, subcutaneous insulin, is burdensome—requiring regular injections or an insulin pump, continuous ...
Sep 8, 2023
0
8
When Richard O'Neil, Ph.D., joined MUSC Hollings Cancer Center two years ago, he knew that he wanted to continue finding ways to make CAR T-cell therapy easier on patients.
Sep 7, 2023
0
57
